nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Dry eye—Betamethasone—psoriatic arthritis	0.00507	0.00507	CcSEcCtD
Apraclonidine—Dry eye—Dexamethasone—psoriatic arthritis	0.00507	0.00507	CcSEcCtD
Apraclonidine—Diarrhoea—Auranofin—psoriatic arthritis	0.00504	0.00504	CcSEcCtD
Apraclonidine—Vomiting—Auranofin—psoriatic arthritis	0.00468	0.00468	CcSEcCtD
Apraclonidine—Dermatitis—Auranofin—psoriatic arthritis	0.00464	0.00464	CcSEcCtD
Apraclonidine—Eye pain—Dexamethasone—psoriatic arthritis	0.00442	0.00442	CcSEcCtD
Apraclonidine—Eye pain—Betamethasone—psoriatic arthritis	0.00442	0.00442	CcSEcCtD
Apraclonidine—Nausea—Auranofin—psoriatic arthritis	0.00437	0.00437	CcSEcCtD
Apraclonidine—Irritability—Methylprednisolone—psoriatic arthritis	0.00418	0.00418	CcSEcCtD
Apraclonidine—Inflammation—Methotrexate—psoriatic arthritis	0.00412	0.00412	CcSEcCtD
Apraclonidine—Irritability—Dexamethasone—psoriatic arthritis	0.00381	0.00381	CcSEcCtD
Apraclonidine—Irritability—Betamethasone—psoriatic arthritis	0.00381	0.00381	CcSEcCtD
Apraclonidine—Asthma—Triamcinolone—psoriatic arthritis	0.0038	0.0038	CcSEcCtD
Apraclonidine—Conjunctivitis—Prednisolone—psoriatic arthritis	0.00358	0.00358	CcSEcCtD
Apraclonidine—Infestation—Methylprednisolone—psoriatic arthritis	0.00338	0.00338	CcSEcCtD
Apraclonidine—Infestation NOS—Methylprednisolone—psoriatic arthritis	0.00338	0.00338	CcSEcCtD
Apraclonidine—Bradycardia—Prednisolone—psoriatic arthritis	0.00336	0.00336	CcSEcCtD
Apraclonidine—Face oedema—Prednisone—psoriatic arthritis	0.00335	0.00335	CcSEcCtD
Apraclonidine—Irritability—Prednisone—psoriatic arthritis	0.00331	0.00331	CcSEcCtD
Apraclonidine—Haemorrhage—Prednisolone—psoriatic arthritis	0.00331	0.00331	CcSEcCtD
Apraclonidine—Conjunctivitis—Triamcinolone—psoriatic arthritis	0.00329	0.00329	CcSEcCtD
Apraclonidine—Visual impairment—Prednisolone—psoriatic arthritis	0.00319	0.00319	CcSEcCtD
Apraclonidine—Bradycardia—Triamcinolone—psoriatic arthritis	0.00309	0.00309	CcSEcCtD
Apraclonidine—Bradycardia—Methylprednisolone—psoriatic arthritis	0.00309	0.00309	CcSEcCtD
Apraclonidine—Rhinitis—Triamcinolone—psoriatic arthritis	0.00305	0.00305	CcSEcCtD
Apraclonidine—Rhinitis—Methylprednisolone—psoriatic arthritis	0.00304	0.00304	CcSEcCtD
Apraclonidine—Haemorrhage—Triamcinolone—psoriatic arthritis	0.00304	0.00304	CcSEcCtD
Apraclonidine—Haemorrhage—Methylprednisolone—psoriatic arthritis	0.00303	0.00303	CcSEcCtD
Apraclonidine—Pharyngitis—Triamcinolone—psoriatic arthritis	0.00302	0.00302	CcSEcCtD
Apraclonidine—Conjunctivitis—Betamethasone—psoriatic arthritis	0.00299	0.00299	CcSEcCtD
Apraclonidine—Conjunctivitis—Dexamethasone—psoriatic arthritis	0.00299	0.00299	CcSEcCtD
Apraclonidine—Arrhythmia—Prednisolone—psoriatic arthritis	0.00295	0.00295	CcSEcCtD
Apraclonidine—Visual impairment—Methylprednisolone—psoriatic arthritis	0.00292	0.00292	CcSEcCtD
Apraclonidine—Erythema—Prednisolone—psoriatic arthritis	0.00288	0.00288	CcSEcCtD
Apraclonidine—Eye disorder—Methylprednisolone—psoriatic arthritis	0.00283	0.00283	CcSEcCtD
Apraclonidine—Bradycardia—Dexamethasone—psoriatic arthritis	0.00281	0.00281	CcSEcCtD
Apraclonidine—Bradycardia—Betamethasone—psoriatic arthritis	0.00281	0.00281	CcSEcCtD
Apraclonidine—Irritability—Methotrexate—psoriatic arthritis	0.00277	0.00277	CcSEcCtD
Apraclonidine—Haemorrhage—Betamethasone—psoriatic arthritis	0.00276	0.00276	CcSEcCtD
Apraclonidine—Haemorrhage—Dexamethasone—psoriatic arthritis	0.00276	0.00276	CcSEcCtD
Apraclonidine—Angiopathy—Methylprednisolone—psoriatic arthritis	0.00275	0.00275	CcSEcCtD
Apraclonidine—Mediastinal disorder—Methylprednisolone—psoriatic arthritis	0.00273	0.00273	CcSEcCtD
Apraclonidine—Arrhythmia—Triamcinolone—psoriatic arthritis	0.00272	0.00272	CcSEcCtD
Apraclonidine—Vision blurred—Prednisolone—psoriatic arthritis	0.00271	0.00271	CcSEcCtD
Apraclonidine—Arrhythmia—Methylprednisolone—psoriatic arthritis	0.00271	0.00271	CcSEcCtD
Apraclonidine—Ill-defined disorder—Prednisolone—psoriatic arthritis	0.00267	0.00267	CcSEcCtD
Apraclonidine—Visual impairment—Betamethasone—psoriatic arthritis	0.00266	0.00266	CcSEcCtD
Apraclonidine—Visual impairment—Dexamethasone—psoriatic arthritis	0.00266	0.00266	CcSEcCtD
Apraclonidine—Mental disorder—Methylprednisolone—psoriatic arthritis	0.00266	0.00266	CcSEcCtD
Apraclonidine—Erythema—Triamcinolone—psoriatic arthritis	0.00265	0.00265	CcSEcCtD
Apraclonidine—Erythema—Methylprednisolone—psoriatic arthritis	0.00264	0.00264	CcSEcCtD
Apraclonidine—Malaise—Prednisolone—psoriatic arthritis	0.00259	0.00259	CcSEcCtD
Apraclonidine—Dysgeusia—Triamcinolone—psoriatic arthritis	0.00259	0.00259	CcSEcCtD
Apraclonidine—Syncope—Prednisolone—psoriatic arthritis	0.00258	0.00258	CcSEcCtD
Apraclonidine—Eye disorder—Dexamethasone—psoriatic arthritis	0.00258	0.00258	CcSEcCtD
Apraclonidine—Eye disorder—Betamethasone—psoriatic arthritis	0.00258	0.00258	CcSEcCtD
Apraclonidine—Asthma—Methotrexate—psoriatic arthritis	0.00251	0.00251	CcSEcCtD
Apraclonidine—Angiopathy—Betamethasone—psoriatic arthritis	0.0025	0.0025	CcSEcCtD
Apraclonidine—Angiopathy—Dexamethasone—psoriatic arthritis	0.0025	0.0025	CcSEcCtD
Apraclonidine—Arrhythmia—Betamethasone—psoriatic arthritis	0.00246	0.00246	CcSEcCtD
Apraclonidine—Arrhythmia—Dexamethasone—psoriatic arthritis	0.00246	0.00246	CcSEcCtD
Apraclonidine—Ill-defined disorder—Triamcinolone—psoriatic arthritis	0.00246	0.00246	CcSEcCtD
Apraclonidine—Ill-defined disorder—Methylprednisolone—psoriatic arthritis	0.00245	0.00245	CcSEcCtD
Apraclonidine—Bradycardia—Prednisone—psoriatic arthritis	0.00245	0.00245	CcSEcCtD
Apraclonidine—Discomfort—Prednisolone—psoriatic arthritis	0.00242	0.00242	CcSEcCtD
Apraclonidine—Abdominal discomfort—Methotrexate—psoriatic arthritis	0.0024	0.0024	CcSEcCtD
Apraclonidine—Haemorrhage—Prednisone—psoriatic arthritis	0.0024	0.0024	CcSEcCtD
Apraclonidine—Erythema—Dexamethasone—psoriatic arthritis	0.0024	0.0024	CcSEcCtD
Apraclonidine—Erythema—Betamethasone—psoriatic arthritis	0.0024	0.0024	CcSEcCtD
Apraclonidine—Malaise—Triamcinolone—psoriatic arthritis	0.00239	0.00239	CcSEcCtD
Apraclonidine—Malaise—Methylprednisolone—psoriatic arthritis	0.00238	0.00238	CcSEcCtD
Apraclonidine—Syncope—Triamcinolone—psoriatic arthritis	0.00237	0.00237	CcSEcCtD
Apraclonidine—Syncope—Methylprednisolone—psoriatic arthritis	0.00237	0.00237	CcSEcCtD
Apraclonidine—Oedema—Prednisolone—psoriatic arthritis	0.00235	0.00235	CcSEcCtD
Apraclonidine—Myalgia—Triamcinolone—psoriatic arthritis	0.00225	0.00225	CcSEcCtD
Apraclonidine—Myalgia—Methylprednisolone—psoriatic arthritis	0.00225	0.00225	CcSEcCtD
Apraclonidine—Eye disorder—Prednisone—psoriatic arthritis	0.00224	0.00224	CcSEcCtD
Apraclonidine—Infestation NOS—Methotrexate—psoriatic arthritis	0.00224	0.00224	CcSEcCtD
Apraclonidine—Infestation—Methotrexate—psoriatic arthritis	0.00224	0.00224	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.00223	0.00223	CcSEcCtD
Apraclonidine—Ill-defined disorder—Dexamethasone—psoriatic arthritis	0.00223	0.00223	CcSEcCtD
Apraclonidine—Ill-defined disorder—Betamethasone—psoriatic arthritis	0.00223	0.00223	CcSEcCtD
Apraclonidine—Discomfort—Triamcinolone—psoriatic arthritis	0.00223	0.00223	CcSEcCtD
Apraclonidine—Discomfort—Methylprednisolone—psoriatic arthritis	0.00222	0.00222	CcSEcCtD
Apraclonidine—Dry mouth—Triamcinolone—psoriatic arthritis	0.0022	0.0022	CcSEcCtD
Apraclonidine—Angiopathy—Prednisone—psoriatic arthritis	0.00218	0.00218	CcSEcCtD
Apraclonidine—Conjunctivitis—Methotrexate—psoriatic arthritis	0.00217	0.00217	CcSEcCtD
Apraclonidine—Malaise—Dexamethasone—psoriatic arthritis	0.00217	0.00217	CcSEcCtD
Apraclonidine—Malaise—Betamethasone—psoriatic arthritis	0.00217	0.00217	CcSEcCtD
Apraclonidine—Oedema—Triamcinolone—psoriatic arthritis	0.00216	0.00216	CcSEcCtD
Apraclonidine—Syncope—Dexamethasone—psoriatic arthritis	0.00215	0.00215	CcSEcCtD
Apraclonidine—Syncope—Betamethasone—psoriatic arthritis	0.00215	0.00215	CcSEcCtD
Apraclonidine—Arrhythmia—Prednisone—psoriatic arthritis	0.00215	0.00215	CcSEcCtD
Apraclonidine—Infection—Triamcinolone—psoriatic arthritis	0.00215	0.00215	CcSEcCtD
Apraclonidine—Infection—Methylprednisolone—psoriatic arthritis	0.00214	0.00214	CcSEcCtD
Apraclonidine—Insomnia—Prednisolone—psoriatic arthritis	0.00212	0.00212	CcSEcCtD
Apraclonidine—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.00211	0.00211	CcSEcCtD
Apraclonidine—Paraesthesia—Prednisolone—psoriatic arthritis	0.00211	0.00211	CcSEcCtD
Apraclonidine—Mental disorder—Prednisone—psoriatic arthritis	0.0021	0.0021	CcSEcCtD
Apraclonidine—Skin disorder—Methylprednisolone—psoriatic arthritis	0.00209	0.00209	CcSEcCtD
Apraclonidine—Erythema—Prednisone—psoriatic arthritis	0.00209	0.00209	CcSEcCtD
Apraclonidine—Myalgia—Betamethasone—psoriatic arthritis	0.00204	0.00204	CcSEcCtD
Apraclonidine—Myalgia—Dexamethasone—psoriatic arthritis	0.00204	0.00204	CcSEcCtD
Apraclonidine—Discomfort—Dexamethasone—psoriatic arthritis	0.00202	0.00202	CcSEcCtD
Apraclonidine—Discomfort—Betamethasone—psoriatic arthritis	0.00202	0.00202	CcSEcCtD
Apraclonidine—Pain—Prednisolone—psoriatic arthritis	0.00201	0.00201	CcSEcCtD
Apraclonidine—Haemorrhage—Methotrexate—psoriatic arthritis	0.00201	0.00201	CcSEcCtD
Apraclonidine—Pharyngitis—Methotrexate—psoriatic arthritis	0.00199	0.00199	CcSEcCtD
Apraclonidine—Vision blurred—Prednisone—psoriatic arthritis	0.00197	0.00197	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.00197	0.00197	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.00196	0.00196	CcSEcCtD
Apraclonidine—Oedema—Dexamethasone—psoriatic arthritis	0.00196	0.00196	CcSEcCtD
Apraclonidine—Oedema—Betamethasone—psoriatic arthritis	0.00196	0.00196	CcSEcCtD
Apraclonidine—Insomnia—Triamcinolone—psoriatic arthritis	0.00195	0.00195	CcSEcCtD
Apraclonidine—Insomnia—Methylprednisolone—psoriatic arthritis	0.00195	0.00195	CcSEcCtD
Apraclonidine—Infection—Dexamethasone—psoriatic arthritis	0.00195	0.00195	CcSEcCtD
Apraclonidine—Infection—Betamethasone—psoriatic arthritis	0.00195	0.00195	CcSEcCtD
Apraclonidine—Ill-defined disorder—Prednisone—psoriatic arthritis	0.00194	0.00194	CcSEcCtD
Apraclonidine—Paraesthesia—Triamcinolone—psoriatic arthritis	0.00194	0.00194	CcSEcCtD
Apraclonidine—Feeling abnormal—Prednisolone—psoriatic arthritis	0.00194	0.00194	CcSEcCtD
Apraclonidine—Paraesthesia—Methylprednisolone—psoriatic arthritis	0.00193	0.00193	CcSEcCtD
Apraclonidine—Visual impairment—Methotrexate—psoriatic arthritis	0.00193	0.00193	CcSEcCtD
Apraclonidine—Dyspnoea—Triamcinolone—psoriatic arthritis	0.00193	0.00193	CcSEcCtD
Apraclonidine—Nervous system disorder—Betamethasone—psoriatic arthritis	0.00192	0.00192	CcSEcCtD
Apraclonidine—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.00192	0.00192	CcSEcCtD
Apraclonidine—Malaise—Prednisone—psoriatic arthritis	0.00189	0.00189	CcSEcCtD
Apraclonidine—Eye disorder—Methotrexate—psoriatic arthritis	0.00188	0.00188	CcSEcCtD
Apraclonidine—Syncope—Prednisone—psoriatic arthritis	0.00188	0.00188	CcSEcCtD
Apraclonidine—Fatigue—Triamcinolone—psoriatic arthritis	0.00186	0.00186	CcSEcCtD
Apraclonidine—Fatigue—Methylprednisolone—psoriatic arthritis	0.00186	0.00186	CcSEcCtD
Apraclonidine—Pain—Triamcinolone—psoriatic arthritis	0.00185	0.00185	CcSEcCtD
Apraclonidine—Angiopathy—Methotrexate—psoriatic arthritis	0.00182	0.00182	CcSEcCtD
Apraclonidine—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.00181	0.00181	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.00179	0.00179	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.00179	0.00179	CcSEcCtD
Apraclonidine—Myalgia—Prednisone—psoriatic arthritis	0.00178	0.00178	CcSEcCtD
Apraclonidine—Feeling abnormal—Triamcinolone—psoriatic arthritis	0.00178	0.00178	CcSEcCtD
Apraclonidine—Feeling abnormal—Methylprednisolone—psoriatic arthritis	0.00178	0.00178	CcSEcCtD
Apraclonidine—Insomnia—Betamethasone—psoriatic arthritis	0.00177	0.00177	CcSEcCtD
Apraclonidine—Insomnia—Dexamethasone—psoriatic arthritis	0.00177	0.00177	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.00177	0.00177	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.00176	0.00176	CcSEcCtD
Apraclonidine—Paraesthesia—Dexamethasone—psoriatic arthritis	0.00176	0.00176	CcSEcCtD
Apraclonidine—Paraesthesia—Betamethasone—psoriatic arthritis	0.00176	0.00176	CcSEcCtD
Apraclonidine—Discomfort—Prednisone—psoriatic arthritis	0.00176	0.00176	CcSEcCtD
Apraclonidine—Mental disorder—Methotrexate—psoriatic arthritis	0.00176	0.00176	CcSEcCtD
Apraclonidine—Erythema—Methotrexate—psoriatic arthritis	0.00175	0.00175	CcSEcCtD
Apraclonidine—Hypersensitivity—Prednisolone—psoriatic arthritis	0.00173	0.00173	CcSEcCtD
Apraclonidine—Dysgeusia—Methotrexate—psoriatic arthritis	0.00171	0.00171	CcSEcCtD
Apraclonidine—Oedema—Prednisone—psoriatic arthritis	0.00171	0.00171	CcSEcCtD
Apraclonidine—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.0017	0.0017	CcSEcCtD
Apraclonidine—Infection—Prednisone—psoriatic arthritis	0.0017	0.0017	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.00169	0.00169	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.00169	0.00169	CcSEcCtD
Apraclonidine—Fatigue—Betamethasone—psoriatic arthritis	0.00169	0.00169	CcSEcCtD
Apraclonidine—Fatigue—Dexamethasone—psoriatic arthritis	0.00169	0.00169	CcSEcCtD
Apraclonidine—Pain—Betamethasone—psoriatic arthritis	0.00168	0.00168	CcSEcCtD
Apraclonidine—Pain—Dexamethasone—psoriatic arthritis	0.00168	0.00168	CcSEcCtD
Apraclonidine—Nervous system disorder—Prednisone—psoriatic arthritis	0.00167	0.00167	CcSEcCtD
Apraclonidine—Skin disorder—Prednisone—psoriatic arthritis	0.00166	0.00166	CcSEcCtD
Apraclonidine—Vision blurred—Methotrexate—psoriatic arthritis	0.00165	0.00165	CcSEcCtD
Apraclonidine—Ill-defined disorder—Methotrexate—psoriatic arthritis	0.00162	0.00162	CcSEcCtD
Apraclonidine—Feeling abnormal—Dexamethasone—psoriatic arthritis	0.00161	0.00161	CcSEcCtD
Apraclonidine—Feeling abnormal—Betamethasone—psoriatic arthritis	0.00161	0.00161	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.0016	0.0016	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.0016	0.0016	CcSEcCtD
Apraclonidine—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.00159	0.00159	CcSEcCtD
Apraclonidine—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.00159	0.00159	CcSEcCtD
Apraclonidine—Malaise—Methotrexate—psoriatic arthritis	0.00158	0.00158	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	0.00155	0.00155	CcSEcCtD
Apraclonidine—Dizziness—Prednisolone—psoriatic arthritis	0.00155	0.00155	CcSEcCtD
Apraclonidine—Asthenia—Triamcinolone—psoriatic arthritis	0.00155	0.00155	CcSEcCtD
Apraclonidine—Abdominal pain—Betamethasone—psoriatic arthritis	0.00155	0.00155	CcSEcCtD
Apraclonidine—Abdominal pain—Dexamethasone—psoriatic arthritis	0.00155	0.00155	CcSEcCtD
Apraclonidine—Asthenia—Methylprednisolone—psoriatic arthritis	0.00155	0.00155	CcSEcCtD
Apraclonidine—Insomnia—Prednisone—psoriatic arthritis	0.00154	0.00154	CcSEcCtD
Apraclonidine—Paraesthesia—Prednisone—psoriatic arthritis	0.00153	0.00153	CcSEcCtD
Apraclonidine—Pruritus—Triamcinolone—psoriatic arthritis	0.00153	0.00153	CcSEcCtD
Apraclonidine—Pruritus—Methylprednisolone—psoriatic arthritis	0.00152	0.00152	CcSEcCtD
Apraclonidine—Chest pain—Methotrexate—psoriatic arthritis	0.00149	0.00149	CcSEcCtD
Apraclonidine—Myalgia—Methotrexate—psoriatic arthritis	0.00149	0.00149	CcSEcCtD
Apraclonidine—Dermatitis—Prednisolone—psoriatic arthritis	0.00148	0.00148	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.00148	0.00148	CcSEcCtD
Apraclonidine—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.00147	0.00147	CcSEcCtD
Apraclonidine—Fatigue—Prednisone—psoriatic arthritis	0.00147	0.00147	CcSEcCtD
Apraclonidine—Headache—Prednisolone—psoriatic arthritis	0.00147	0.00147	CcSEcCtD
Apraclonidine—Discomfort—Methotrexate—psoriatic arthritis	0.00147	0.00147	CcSEcCtD
Apraclonidine—Constipation—Prednisone—psoriatic arthritis	0.00146	0.00146	CcSEcCtD
Apraclonidine—Dizziness—Triamcinolone—psoriatic arthritis	0.00143	0.00143	CcSEcCtD
Apraclonidine—Dizziness—Methylprednisolone—psoriatic arthritis	0.00142	0.00142	CcSEcCtD
Apraclonidine—Infection—Methotrexate—psoriatic arthritis	0.00142	0.00142	CcSEcCtD
Apraclonidine—Feeling abnormal—Prednisone—psoriatic arthritis	0.00141	0.00141	CcSEcCtD
Apraclonidine—Asthenia—Dexamethasone—psoriatic arthritis	0.00141	0.00141	CcSEcCtD
Apraclonidine—Asthenia—Betamethasone—psoriatic arthritis	0.00141	0.00141	CcSEcCtD
Apraclonidine—Nervous system disorder—Methotrexate—psoriatic arthritis	0.0014	0.0014	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.0014	0.0014	CcSEcCtD
Apraclonidine—Nausea—Prednisolone—psoriatic arthritis	0.00139	0.00139	CcSEcCtD
Apraclonidine—Pruritus—Dexamethasone—psoriatic arthritis	0.00139	0.00139	CcSEcCtD
Apraclonidine—Pruritus—Betamethasone—psoriatic arthritis	0.00139	0.00139	CcSEcCtD
Apraclonidine—Skin disorder—Methotrexate—psoriatic arthritis	0.00139	0.00139	CcSEcCtD
Apraclonidine—Vomiting—Triamcinolone—psoriatic arthritis	0.00137	0.00137	CcSEcCtD
Apraclonidine—Vomiting—Methylprednisolone—psoriatic arthritis	0.00137	0.00137	CcSEcCtD
Apraclonidine—Dermatitis—Triamcinolone—psoriatic arthritis	0.00136	0.00136	CcSEcCtD
Apraclonidine—Dermatitis—Methylprednisolone—psoriatic arthritis	0.00136	0.00136	CcSEcCtD
Apraclonidine—Headache—Triamcinolone—psoriatic arthritis	0.00135	0.00135	CcSEcCtD
Apraclonidine—Headache—Methylprednisolone—psoriatic arthritis	0.00135	0.00135	CcSEcCtD
Apraclonidine—Abdominal pain—Prednisone—psoriatic arthritis	0.00135	0.00135	CcSEcCtD
Apraclonidine—Diarrhoea—Dexamethasone—psoriatic arthritis	0.00134	0.00134	CcSEcCtD
Apraclonidine—Diarrhoea—Betamethasone—psoriatic arthritis	0.00134	0.00134	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	0.0013	0.0013	CcSEcCtD
Apraclonidine—Dizziness—Betamethasone—psoriatic arthritis	0.0013	0.0013	CcSEcCtD
Apraclonidine—Dizziness—Dexamethasone—psoriatic arthritis	0.0013	0.0013	CcSEcCtD
Apraclonidine—Insomnia—Methotrexate—psoriatic arthritis	0.00129	0.00129	CcSEcCtD
Apraclonidine—Nausea—Triamcinolone—psoriatic arthritis	0.00128	0.00128	CcSEcCtD
Apraclonidine—Paraesthesia—Methotrexate—psoriatic arthritis	0.00128	0.00128	CcSEcCtD
Apraclonidine—Nausea—Methylprednisolone—psoriatic arthritis	0.00128	0.00128	CcSEcCtD
Apraclonidine—Dyspnoea—Methotrexate—psoriatic arthritis	0.00127	0.00127	CcSEcCtD
Apraclonidine—Somnolence—Methotrexate—psoriatic arthritis	0.00127	0.00127	CcSEcCtD
Apraclonidine—Hypersensitivity—Prednisone—psoriatic arthritis	0.00126	0.00126	CcSEcCtD
Apraclonidine—Vomiting—Dexamethasone—psoriatic arthritis	0.00125	0.00125	CcSEcCtD
Apraclonidine—Vomiting—Betamethasone—psoriatic arthritis	0.00125	0.00125	CcSEcCtD
Apraclonidine—Dermatitis—Dexamethasone—psoriatic arthritis	0.00123	0.00123	CcSEcCtD
Apraclonidine—Dermatitis—Betamethasone—psoriatic arthritis	0.00123	0.00123	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.00123	0.00123	CcSEcCtD
Apraclonidine—Fatigue—Methotrexate—psoriatic arthritis	0.00123	0.00123	CcSEcCtD
Apraclonidine—Headache—Dexamethasone—psoriatic arthritis	0.00123	0.00123	CcSEcCtD
Apraclonidine—Headache—Betamethasone—psoriatic arthritis	0.00123	0.00123	CcSEcCtD
Apraclonidine—Asthenia—Prednisone—psoriatic arthritis	0.00122	0.00122	CcSEcCtD
Apraclonidine—Pain—Methotrexate—psoriatic arthritis	0.00122	0.00122	CcSEcCtD
Apraclonidine—Pruritus—Prednisone—psoriatic arthritis	0.00121	0.00121	CcSEcCtD
Apraclonidine—Feeling abnormal—Methotrexate—psoriatic arthritis	0.00118	0.00118	CcSEcCtD
Apraclonidine—Diarrhoea—Prednisone—psoriatic arthritis	0.00117	0.00117	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.00117	0.00117	CcSEcCtD
Apraclonidine—Nausea—Dexamethasone—psoriatic arthritis	0.00116	0.00116	CcSEcCtD
Apraclonidine—Nausea—Betamethasone—psoriatic arthritis	0.00116	0.00116	CcSEcCtD
Apraclonidine—Dizziness—Prednisone—psoriatic arthritis	0.00113	0.00113	CcSEcCtD
Apraclonidine—Abdominal pain—Methotrexate—psoriatic arthritis	0.00113	0.00113	CcSEcCtD
Apraclonidine—Vomiting—Prednisone—psoriatic arthritis	0.00108	0.00108	CcSEcCtD
Apraclonidine—Dermatitis—Prednisone—psoriatic arthritis	0.00107	0.00107	CcSEcCtD
Apraclonidine—Headache—Prednisone—psoriatic arthritis	0.00107	0.00107	CcSEcCtD
Apraclonidine—Hypersensitivity—Methotrexate—psoriatic arthritis	0.00105	0.00105	CcSEcCtD
Apraclonidine—Asthenia—Methotrexate—psoriatic arthritis	0.00102	0.00102	CcSEcCtD
Apraclonidine—Nausea—Prednisone—psoriatic arthritis	0.00101	0.00101	CcSEcCtD
Apraclonidine—Pruritus—Methotrexate—psoriatic arthritis	0.00101	0.00101	CcSEcCtD
Apraclonidine—Diarrhoea—Methotrexate—psoriatic arthritis	0.000976	0.000976	CcSEcCtD
Apraclonidine—Dizziness—Methotrexate—psoriatic arthritis	0.000943	0.000943	CcSEcCtD
Apraclonidine—Vomiting—Methotrexate—psoriatic arthritis	0.000907	0.000907	CcSEcCtD
Apraclonidine—Dermatitis—Methotrexate—psoriatic arthritis	0.000898	0.000898	CcSEcCtD
Apraclonidine—Headache—Methotrexate—psoriatic arthritis	0.000893	0.000893	CcSEcCtD
Apraclonidine—Nausea—Methotrexate—psoriatic arthritis	0.000847	0.000847	CcSEcCtD
